Li Jing, Pang Huayang, Sun Hao, Liu Xiaoyu
Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, China.
Front Oncol. 2025 Jul 24;15:1599075. doi: 10.3389/fonc.2025.1599075. eCollection 2025.
The prognostic importance of the pretreatment pan-immune-inflammation value (PIV) in colorectal cancer has been extensively documented, yet its role remains unclear. This study aims to conduct an updated meta-analysis to elucidate the relationship between the pretreatment PIV and long-term survival outcomes among patients diagnosed with colorectal cancer.
A systematic literature review was performed in PubMed, Embase, Web of Science and CNKI to identify eligible studies from inception to January 18, 2025. The primary endpoints evaluated were survival outcomes. Hazard ratios (HRs) along with their corresponding 95% confidence intervals (CIs) for survival outcomes were extracted. A random-effects model was utilized to synthesize the findings. All statistical analyses were conducted using R software, version 4.2.1.
Out of 81 identified studies, a total of 14 retrospective studies including 6,192 colorectal cancer patients were ultimately included. In this meta-analysis, the pooled results demonstrated that patients with higher PIV exhibited significantly poorer overall survival (11 studies, HR=1.95; 95%CI:1.64-2.31; P<0.01; I = 34%) and disease-free survival (10 studies, HR= 1.89; 95% CI: 1.48-2.41; P < 0.01; I = 66%). Furthermore, evidence pooled from two studies demonstrated that PIV may be an independent prognostic factor for cancer-specific survival (HR= 2.61; 95% CI: 1.56-4.38; P < 0.01; I = 0%).
Our study reveals that the pretreatment PIV can serve as a valuable biomarker for predicting long-term survival outcomes in patients with colorectal cancer, which may have important clinical implications for personalized treatment strategies.
结直肠癌患者治疗前的全免疫炎症值（PIV）对预后的重要性已有大量文献记载，但其作用仍不明确。本研究旨在进行一项更新的荟萃分析，以阐明治疗前PIV与结直肠癌患者长期生存结局之间的关系。
在PubMed、Embase、Web of Science和中国知网进行系统的文献综述，以确定从研究开始至2025年1月18日的符合条件的研究。评估的主要终点是生存结局。提取生存结局的风险比（HR）及其相应的95%置信区间（CI）。采用随机效应模型综合研究结果。所有统计分析均使用R软件4.2.1版进行。
在81项已识别的研究中，最终纳入了14项回顾性研究，共6192例结直肠癌患者。在这项荟萃分析中，汇总结果表明，PIV较高的患者总生存期（11项研究，HR=1.95；95%CI：1.64-2.31；P<0.01；I²=34%）和无病生存期（10项研究，HR=1.89；95%CI：1.48-2.41；P<0.01；I²=66%）明显较差。此外，两项研究汇总的证据表明，PIV可能是癌症特异性生存的独立预后因素（HR=2.61；95%CI：1.56-4.38；P<0.01；I²=0%）。
我们的研究表明，治疗前PIV可作为预测结直肠癌患者长期生存结局的有价值的生物标志物，这可能对个性化治疗策略具有重要的临床意义。
